TLV’s Myalepta decision shows how rare-disease flexibility still needs subgroup value, severity, and negotiated cost to support reimbursement.
https://www.mattheneus.com/editorial/tlv-myalepta-generalised-lipodystrophy-limited-reimbursement-2026-04-25 #HTA #Pharma #RegulatoryAffairs
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) limits Myalepta reimbursement to generalised lipodystrophy after subgroup value review
Sweden's Dental and Pharmaceutical Benefits Agency (TLV) restricted Myalepta reimbursement to generalised lipodystrophy from 1 March 2026. TLV accepted best supportive care as the comparator and recognised metabolic benefit on glycated haemoglobin and triglycerides, but judged the cost reasonable only for the generalised subgroup after a side agreement reduced treatment costs.
Sweden’s TLV framed Vevizye as a restricted reimbursement case: comparable effect to Ikervis, equal daily medicine cost, and no implied superiority claim.
https://www.mattheneus.com/editorial/tlv-vevizye-ciclosporin-limited-reimbursement-ikervis-cost-comparison-2026-04-28 #HTA #Pharma #RegulatoryAffairs
Sweden limits Vevizye reimbursement to severe dry eye syndrome after Ikervis cost comparison
Sweden's TLV added Vevizye to the pharmaceutical benefits scheme with restricted reimbursement from 28 April 2026. The decision relies on likely comparable effect to Ikervis and equal daily medicine cost, not a new superiority claim.
Trial retention and outcome-data completeness now need a dedicated HTA governance plan
A 20 April 2026 BMJ Open synthesis of participant reasons for trial non-completion turns retention into a concrete evidence-design problem for health technology assessment. When outcome data go missing, comparative estimates, utility inputs, and reimbursement models all become harder to defend.
Target trial emulation is getting harder to ignore in HTA: registry-based RWD shifted the ICER for post-first-line RA biologics from ~£34.7k to ~£46.8k/QALY.
https://www.mattheneus.com/editorial/target-trial-emulation-rwd-cost-effectiveness-hta-playbook-2026-04-03 #HTA #RWE #HealthEconomics
Target Trial Emulation May Be the Missing Bridge Between Real-World Data and Cost-Effectiveness in Health Technology Assessment
On 3 April 2026, Singh and colleagues published a Med Decision Making study showing that target trial emulation using registry-based real-world data changed the estimated cost effectiveness of biologic treatment after first-line failure in rheumatoid arthritis, lifting the incremental cost-effectiveness ratio from about £34,700 per quality-adjusted life-year in the randomized-trial-only analysis to about £46,800 when real-world evidence informed the estimate.
CAR-T access is no longer just a clinical story; HTA timing and cost-effectiveness design now shape who gets to market and when.
https://www.mattheneus.com/editorial/car-t-global-hta-access-lag-cost-effectiveness-playbook-2026-04-02
#HTA #HealthEconomics #Pharma
Commercial chimeric antigen receptor (CAR) T-cell access now depends on earlier health technology assessment (HTA) and cost-effectiveness design
A new 2 April 2026 Blood analysis shows that commercial chimeric antigen receptor (CAR) T-cell access is being constrained as much by health technology assessment (HTA) timing and cost-effectiveness uncertainty as by manufacturing, forcing evidence teams to pre-build comparative and economic strategy before approval.
The UK just made non-animal evidence planning more real: MHRA’s new advance Module 4 review route gives teams an earlier read on whether their package will hold up.
https://www.mattheneus.com/editorial/mhra-non-animal-methods-module-4-advance-review-guidance-2026-04-02 #HTA #RegulatoryAffairs #Pharma
Medicines and Healthcare products Regulatory Agency (MHRA) opens an advance Module 4 review route for medicines developed without animal studies
Medicines and Healthcare products Regulatory Agency (MHRA) now offers a clearer regulatory route for medicines developed without animal studies, including an advance Module 4 review mechanism by end-2026 and sharper expectations for how teams justify safety, mechanism, and evidence use in health technology assessment (HTA) and regulatory planning.
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs.
https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
AbangeLabs HTA Studio: From ITC Foundation to End-to-End HTA Evidence Platform
Health technology assessment (HTA) evidence teams are increasingly asked to deliver multi-method evidence packages spanning indirect treatment comparison (ITC), matching-adjusted indirect comparison (MAIC), network meta-analysis (NMA), economic modelling, and reporting. This article examines why fragmented execution is becoming a methodological governance risk and how AbangeLabs HTA Studio addresses that problem through documented current capabilities.
HTA submissions keep breaking where comparative evidence meets the economic model. If the lineage is not traceable, cost-effectiveness and budget-impact claims turn fragile fast.
https://www.mattheneus.com/editorial/hta-submissions-comparative-evidence-economic-model-lineage-problem-2026-04-02 #HTA #HealthEconomics #RegulatoryAffairs
Health technology assessment submissions now face a comparative-evidence to economic-model lineage problem
Health technology assessment (HTA) teams increasingly need cost-effectiveness and budget-impact outputs that remain directly traceable to the comparative evidence behind them. This article examines why broken lineage between analysis and modelling has become a submission risk and how AbangeLabs HTA Studio addresses that integration problem through verified current capabilities.
Eastern Europe and Central Asia need a health technology assessment (HTA) capacity-building playbook, not one-off pilots
A 30 March 2026 International Journal of Technology Assessment in Health Care review shows that Eastern Europe and Central Asia are moving toward broader health technology assessment (HTA) use, but uneven staffing, training, and governance mean evidence teams need reusable cross-market comparative and economic packages rather than one-off country submissions.
Germany opens reimbursable Long/Post-COVID off-label use for four medicines
Germany's Federal Joint Committee has moved four Long/Post-COVID off-label recommendations into reimbursable care. The evidence basis is uneven across the package: metformin is anchored in the COVID-OUT randomised controlled trial, while ivabradine, vortioxetine and agomelatine rely on smaller symptom-specific studies with important transferability and bias questions.
AbangeLabs